Type 2 Immune-Dominant Endotype Is Not Associated With Increased Responsiveness to Dupilumab Treatment in Adult Atopic Dermatitis Patients

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • Coco Dekkers - , University Medical Center (UMC) Utrecht (Author)
  • Hidde Smits - , University Medical Center (UMC) Utrecht (Author)
  • Dora Stölzl - , Universitätsmedizin Mannheim (Author)
  • Lotte Spekhorst - , University Medical Center (UMC) Utrecht (Author)
  • Edward Knol - , University Medical Center (UMC) Utrecht (Author)
  • Femke van Wijk - , University Medical Center (UMC) Utrecht (Author)
  • Inken Harder - , Universitätsmedizin Mannheim (Author)
  • Thomas Werfel - , Hannover Medical School (MHH) (Author)
  • Jochen Schmitt - , Center for Evidence-Based Healthcare, Medical Faculty Carl Gustav Carus (Author)
  • Andreas Kleinheinz - , Elbe Clinics Stade/Buxtehude (Author)
  • Susanne Abraham - , University Allergy Centre, University Hospital Carl Gustav Carus Dresden (Author)
  • Judith Thijs - , Meander Medical Center (Author)
  • Stephan Weidinger - , Universitätsmedizin Mannheim (Author)
  • Marjolein de Bruin-Weller - , University Medical Center (UMC) Utrecht (Author)
  • Daphne Bakker - , University Medical Center (UMC) Utrecht (Author)
  • Julia Drylewicz - , University Medical Center (UMC) Utrecht (Author)

Abstract

Summary

Type 2-dominant endotype is not associated with increased responsiveness to dupilumab in AD patients.
This study finds no biological evidence to exclude AD patients from considering dupilumab treatment.

Details

Original languageEnglish
Pages (from-to)97-99
Number of pages3
JournalClinical and Experimental Allergy
Volume55
Issue number1
Publication statusPublished - Jan 2025
Peer-reviewedYes

External IDs

Scopus 85207624138
PubMed 39449187
PubMedCentral PMC11707302

Keywords